From the Department of Pediatrics, Division of Environmental Pediatrics, NYU Langone Medical Center, New York, NY, 10016, USA (SS, LT, AG, MHJ); Department of Population Health, NYU Langone Medical Center, New York, NY, 10016, USA (LT, AG); Department of Environmental Medicine, NYU Langone Medical Center, New York, NY, 10016, USA (LT, AG); NYU Wagner School of Public Service, New York, NY, USA (LT); NYU College of Global Public Health, New York, NY, USA (LT); Department of Obstetrics and Gynecology, NYU Langone Medical Center, New York, NY 10016 USA (SSM-L, SGB).
J Addict Med. 2022;16(4):e225-e233. doi: 10.1097/ADM.0000000000000921. Epub 2021 Sep 22.
To estimate the prevalence of perinatal cannabis use (ie, before and/or during pregnancy); document the frequency, modes, and motivations for use; and identify predictors of perinatal cannabis use.
Six states in the Pregnancy Risk Assessment Monitoring System, a state-specific, population-based surveillance system, administered a supplemental questionnaire on perinatal cannabis use in 2016-2018. Women with live births were surveyed 2-6 months postpartum about behaviors ≤ 3 months preconception and during pregnancy. Demographic, psychosocial, and behavioral characteristics were examined in relation to perinatal cannabis use using multinomial regression models. Those who: (1) never used cannabis, (2) only used in preconception period, and (3) used in both preconception and prenatal periods were compared.
Among 6428 respondents, 379 (5.8%) used cannabis pre-conceptionally only and 466 (4.4%) used in both the preconception and prenatal periods. Among those using prenatally, most reported smoking as their single mode (87.1%), with the two most common reasons being stress (83.8%) and nausea/vomiting (79.2%). Marital status, race/ethnicity, socioeconomic status, parity, and cigarette and alcohol use were significantly associated with perinatal cannabis use. Single (vs partnered) women were more likely to use cannabis prenatally (odds ratio = 2.4, 95% confidence interval: 1.5, 3.9) and non-Hispanic Black (vs White) women were less likely to use prenatally (odds ratio = 0.4, 95% confidence interval: 0.2, 0.8).
Using a population-based sample of US births in six states, several demographic, psychosocial, and behavioral characteristics were identified in relation to perinatal cannabis use. These data are valuable for counseling in prenatal care and investigations of health effects.
评估围产期大麻使用（即在怀孕前和/或怀孕期间使用）的流行率；记录使用的频率、方式和动机；并确定围产期大麻使用的预测因素。
2016 年至 2018 年，在妊娠风险评估监测系统（一种基于人群的特定州监测系统）的 6 个州，对围产期大麻使用情况进行了补充问卷调查。对产后 2-6 个月的活产妇女进行调查，了解 ≤3 个月孕前和怀孕期间的行为。使用多项回归模型，检查与围产期大麻使用相关的人口统计学、心理社会和行为特征。比较以下三种人群：（1）从未使用大麻的人；（2）仅在孕前使用的人；（3）在孕前和孕期都使用的人。
在 6428 名受访者中，379 名（5.8%）仅在孕前使用大麻，466 名（4.4%）在孕前和孕期都使用大麻。在那些孕期使用大麻的人中，大多数人报告单一使用方式为吸烟，最常见的两个原因是压力（83.8%）和恶心/呕吐（79.2%）。婚姻状况、种族/族裔、社会经济地位、产次以及吸烟和饮酒与围产期大麻使用显著相关。与伴侣关系的女性（vs 单身女性）更有可能在孕期使用大麻（优势比=2.4，95%置信区间：1.5，3.9），而非西班牙裔黑人（vs 白人）女性更不可能在孕期使用大麻（优势比=0.4，95%置信区间：0.2，0.8）。
使用来自六个州的美国出生人口的基于人群的样本，确定了与围产期大麻使用相关的一些人口统计学、心理社会和行为特征。这些数据对于产前保健中的咨询和对健康影响的调查非常有价值。
